2-甲基-5-[[(2S)-环氧乙烷-2-基]甲氧基]-1,3-苯并噻唑 | 256420-60-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻唑类
• 中文名称: 2-甲基-5-[[(2S)-环氧乙烷-2-基]甲氧基]-1,3-苯并噻唑
• 中文别名: 苯并噻唑,2-甲基-5-[(2S)-2-噁丙环基甲氧基]-
• 英文名称: 5-[((2S)oxiran-2-yl)methoxy]-2-methylbenzothiazole
• 英文别名: 2-methyl-5-(S)-(oxiran-2-ylmethoxy)benzothiazole；(S)-glycidyl 2-methylbenzothiazol-5-yl ether；2-methyl-5-[[(2S)-oxiran-2-yl]methoxy]-1,3-benzothiazole
• CAS: 256420-60-7
• 化学式: C₁₁H₁₁NO₂S
• 分子量: 221.28
• InChiKey: YSPRCDGVFRVBED-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  62.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-(2,6-二甲基苯基)-1-哌嗪乙酰胺 、 2-甲基-5-[[(2S)-环氧乙烷-2-基]甲氧基]-1,3-苯并噻唑 以 乙醇 为溶剂， 生成 2-{4-[(2S)-2-hydroxy-3-(2-methylbenzothiazol-5-yloxy)propyl]piperazinyl}-N-(2,6-dimethylphenyl)acetamide
  参考文献：
  名称：

  Novel inhibitors of fatty acid oxidation as potential metabolic modulators

  摘要：

  We describe the synthesis of novel inhibitors of fatty acid oxidation as potential metabolic modulators for the treatment of stable angina. Replacement of the 2H-benzo[d]1,3-dioxolene ring system in our initial lead 3 with different benzthiazoles, benzoxazoles and introducing small alkyl substituents into the piperazine ring resulted in analogues with enhanced inhibitory activity against 1-(14)[C]-palmitoyl-CoA oxidation in isolated rat heart mitochondria (6, IC50 = 70 nM; 25, IC50 = 23 nM). (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.11.065
• 作为产物：
  描述：

  2-甲基-5-苯并噻唑 、 右旋环氧氯丙烷 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 生成 2-甲基-5-[[(2S)-环氧乙烷-2-基]甲氧基]-1,3-苯并噻唑
  参考文献：
  名称：

  Heteroaryl alkyl piperazine derivatives

  摘要：

  一种通式为的新化合物及其药学上可接受的酸盐，其中这些化合物在治疗中对保护骨骼肌免受创伤造成的损伤或保护骨骼肌在肌肉或全身性疾病（如间歇性跛行）、治疗休克状态、保存供体组织和器官用于移植、治疗糖尿病、治疗心血管疾病包括心房和心室心律失常、普林斯梅塔尔（变异）心绞痛、稳定型心绞痛和运动诱发性心绞痛、充血性心力衰竭和心肌梗死等方面具有用处。

  公开号：

  US06849632B2

文献信息

• Substituted heterocyclic compounds
  申请人：——

  公开号：US20030176447A1

  公开（公告）日：2003-09-18

  Disclosed are novel heterocyclic derivatives, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes, and for increasing HDL plasma levels in mammals.

  揭示了一种新颖的杂环衍生物，用于治疗各种疾病状态，特别是心血管疾病，如心房和心室心律失常、间歇性跛行、普林兹梅塔（变异）心绞痛、稳定和不稳定心绞痛、运动诱发性心绞痛、充血性心力衰竭和心肌梗死。这些化合物还可用于治疗糖尿病，并可增加哺乳动物的高密度脂蛋白血浆水平。
• Use of 5HT-1F receptor antagonists for treating anxiety disorders
  申请人：ELI LILLY AND COMPANY

  公开号：EP0976747A3

  公开（公告）日：2000-09-13

  The present invention provides a method for the treatment of prevention of anxiety disorders which comprises administering to a mammal in need of such treatment a serotonin 5-HT1F receptor antagonist.

  本发明提供了一种治疗预防焦虑症的方法，包括向需要此类治疗的哺乳动物施用一种5-HT1F受体拮抗剂。
• 5-HT1F antagonists
  申请人：Eli Lilly and Company

  公开号：US06242450B1

  公开（公告）日：2001-06-05

  This invention provides 5-HT1f antagonists of Formula I: where AR1, AR2, R, and R′ are as defined in the specification.

  这项发明提供了化学式I中的5-HT1f拮抗剂：其中AR1、AR2、R和R'如规范中所定义。
• [EN] SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL IN THE TREATMENT OF CARDIOVASCULAR DISEASES<br/>[FR] COMPOSES HETEROCYCLIQUES SUBSTITUES UTILES POUR LE TRAITEMENT DE MALADIES CARDIO-VASCULAIRES
  申请人：CV THERAPEUTICS INC

  公开号：WO2004069818A1

  公开（公告）日：2004-08-19

  wherein: a.o. T is oxygen, sulfur, or NR11 , in which R11 is hydrogen or lower alkyl; V is -N<, -CH<, or -NH-CH<; X1 is hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; X2 is optionally substituted aryl or optionally substituted heteroaryl; Y is optionally substituted dihydroheteroarcyl; and Z1 and Z2 are independently optionally substituted alkylene of 1-4 carbon atoms, useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal’s (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes.

  其中：a.o. T是氧、硫或NR11，其中R11是氢或较低的烷基；V是-N<，-CH<或-NH-CH<；X1是氢，可选择取代的较低烷基，可选择取代的环烷基，可选择取代的芳基或可选择取代的杂芳基；X2是可选择取代的芳基或可选择取代的杂芳基；Y是可选择取代的二氢杂芳基；Z1和Z2分别是1-4个碳原子的可选择取代的烷基，用于治疗各种疾病状态，特别是心血管疾病，如心房和心室心律失常、间歇性跛行、普林兹梅塔（变异）心绞痛、稳定和不稳定心绞痛、运动诱发性心绞痛、充血性心脏病和心肌梗死。这些化合物还可用于治疗糖尿病。
• [EN] SUBSTITUTED PIPERAZINE COMPOUNDS AND THEIR USE AS FATTY ACID OXIDATION INHIBITORS<br/>[FR] COMPOSES DE PIPERAZINE SUBSTITUES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE L'OXYDATION D'ACIDES GRAS
  申请人：CV THERAPEUTICS INC

  公开号：WO2003008411A1

  公开（公告）日：2003-01-30

  Disclosed are novel heterocyclic derivatives of the formula (I), wherein amongst others R?1, R2, R3, R4, R5, R6, R7, and R8¿ are hydrogen; T is oxygen, sulfur, or NR11, in which R11 is hydrogen or lower alkyl; V is N<, -CH<, or N-CH<; X1 is hydrogen, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl; X2 is optionally substituted aryl or optionally substituted heteroaryl; Y is optionally substituted monocyclic heteroarylenyl; and Z?1 and Z2¿ are independently optionally substituted alkylene or 1-4 carbon atoms. The compounds are useful for the treatment of various disease states, in particular cardiovascular diseases such as atrial and ventricular arrhythmias, intermittent claudication, Prinzmetal's (variant) angina, stable and unstable angina, exercise induced angina, congestive heart disease, and myocardial infarction. The compounds are also useful in the treatment of diabetes, and for increasing HDL plasma levels in mammals.

  本发明涉及一种新型杂环衍生物的公开式（I），其中，R1、R2、R3、R4、R5、R6、R7和R8中的一些是氢；T为氧、硫或NR11，其中R11为氢或低碳基；V为N<、-CH<或N-CH<；X1为氢、可选取代的低碳基、可选取代的环烷基、可选取代的芳基或可选取代的杂环芳基；X2为可选取代的芳基或可选取代的杂环芳基；Y为可选取代的单环杂芳基；Z1和Z2独立地为可选取代的烷基或1-4碳原子。该化合物可用于治疗各种疾病状态，特别是心血管疾病，如心房和心室心律失常、间歇性跛行、普林兹梅塔尔（变异型）心绞痛、稳定和不稳定性心绞痛、运动诱发性心绞痛、充血性心力衰竭和心肌梗死。该化合物还可用于治疗糖尿病，并可提高哺乳动物的高密度脂蛋白血浆水平。